Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Type1_Research_Developments_6-2020
…● We supported Acceleron Pharmaceuticals’ efforts (since ended) to strengthen affected muscles in individuals with demyelinating CMT. DEMYELINATING CMT: TYPE 1, TYPE X AND TYPE 4 STAR RESEARCH DEVELOPMENTS ●…
NJ/NYC Focus Group with Acceleron Pharma
The goal of Patients as Partners in Research is to advance the work of our Strategy to Accelerate Research (STAR) and enroll the patient community in the critical work of…
Inside Innovation | Education Event & Lab Tour
04/09/2025 @ 12:30 pm – 4:30 pm – Join us for a special event with CMTA-STAR Alliance Partner, Actio Biosciences on Wednesday, April 9 from 12:30 p.m. – 4:30 p.m. Pacific Time. CMT community members are invited to spend the afternoon learning about the world-class research Actio Biosciences is doing in CMT 2C/TRPV4+, and attendees will also get to tour Actio Biosciences research […]
CMTA Announces New Center of Excellence at Duke University Hospital
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is thrilled…
Type1_Research_Developments
CMTAUSA.ORG over, please Demyelinating CMT: Type 1, Type X and Type 4 Research Developments In a multipronged approach to identifying novel treatments for demyelinating CMT, the CMTA is pursuing several…
Novartis Secures $1.3B Deal for CMT Treatment CKD-510
…portfolio. The significance of this collaboration is underscored by the substantial financial investment and the broader landscape of CMT research. HDAC6 has long been a focal point of CMT research,…
CMTA-Funded Study on 3-D Printing Technique for Comparing CMT Heel Surgeries Named Game Changer at AAOS Meeting
…the second phase of the research to see what type of reconstructive procedure is best. That research should be completed in six months. One in 2,500 people has the genetic…
Invitae Announces Major Expansion of Its Neurology Test Offerings
…17 existing neurology panels based on new discoveries in genetics research. With this latest expansion of its test offerings, Invitae will be able to provide clinicians, patients, and payers with…
New Mobile App Simplifies Sign-Up for Patient Registry
A new mobile app developed by the Rare Diseases Clinical Research Network (RDCRN) makes it easier than ever for CMT patients to sign up for and navigate the network’s patient…
Volunteer Spotlight: Amy Keller
…covered with the CMTA STARS Amy has sold to raise funds for CMT research. One fateful day, Amy recalls, she decided she was tired of feeling down about her diagnosis…